Get started
Author

Koteswararao Vemula

Observed names: K. Vemula, Koteswara Rao Vemula, Vemula Koteswararao
Institution: Sogang University
ORCID: 0000-0002-3826-0145
Observed ORCID: 0000-0002-3826-0145
OpenAlex ID: A5084858415
Process optimization and modeling of lead removal using iron oxide nanocomposites generated from bio-waste mass
2019 · Lakshmi Prasanna Lingamdinne, Koteswara Rao Vemula, et al. · Chemosphere · 104
CNT facilitated interfacial charge transfer of TiO2 nanocomposite for controlling the electron-hole recombination
2020 · Hitesh Kumar Sharma, Sanjeev K. Sharma, et al. · Solid State Sciences · 69
Photocatalytic performance of yttrium-doped CNT-ZnO nanoflowers synthesized from hydrothermal method
2021 · S.K. Sharma, R. Gupta, et al. · Materials Today Chemistry · 67
A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2019 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al. · Molecular Cancer Therapeutics · 63
Synthesis of monodisperse mesoporous TiO2 spheres with tunable sizes between 0.6 and 3.1 μm and effects of reaction temperature, Ti source purity, and type of alkylamine on size and monodispersity
2012 · Myun Pyo Hong, Jang Yong Kim, et al. · Chemical Communications · 28
On the green emission of holmium (III) doped LaVO4 phosphors
2021 · Vijay Singh, Puja Kumari, et al. · Optik · 12
Low-Overpotential Hydrogen Evolution Reaction Electrode Loaded with Very Small Amounts of PtPd Alloy Nanoparticles
2023 · Koteswararao Vemula, Do Xuan Ha, et al. · ACS Applied Nano Materials · 9
Data from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al. · 1
(Digital Presentation) Metal Alloy Nanoparticles Dispersed in Amorphous Titanosilicate for Hydrogen Evolution Reaction Catalyst with Much Lower Overpotential Than That of Benchmark Catalyst in a Wide pH Range
2023 · Koteswararao Vemula · ECS Meeting Abstracts
Supplementary Figure 3 NP-12 increased the levels of IFN-γ in the Tetanus toxoid recall assay from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Figure 2 Elevated production of IFN-γ by NP-12 in Staphylococcus Enterotoxin B (SEB) stimulated human PBMCs from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Table 1 from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Materials and Methods from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Figure 1 NP-12 labeled with FITC shows higher binding to CHOK1 cells overexpressing PD-L1 as compared to WT CHOK1 cells from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Figure 4 NP-12 increased the levels of IFN-γ in the Cytomegalovirus (CMV) antigen recall assay from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Figure 5 Pharmacokinetic profile of NP-12 from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Supplementary Figure 5 Pharmacokinetic profile of NP-12 from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Data from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
2023 · Pottayil G. Sasikumar, Raghuveer K. Ramachandra, et al.
Works count: 18
Citation count: 353
H-index: 7
I10-index: 6
Year
Topic
Type